Digoxin-Induced Anemia Among Patients With Atrial Fibrillation And Heart Failure: Clinical Data Analysis And Drug-Gene Interaction Network

The study analyzed data from the FDA Adverse Event Reporting System to investigate the link between digoxin and anemia in patients with atrial fibrillation and heart failure. It included 75,618 atrial fibrillation patients and 15,699 heart failure patients. The findings showed that digoxin treatment was significantly associated with a higher likelihood of anemia adverse reactions compared to other therapies, with odds ratios of 1.38 for atrial fibrillation patients and 1.50 for heart failure patients. Additionally, 821 human genes interacting with digoxin were identified, with functional analysis revealing significant enrichment in iron transport processes, related to iron deficiency anemia. The study concluded that the association between digoxin and anemia should be considered in clinical practice, and further research on the toxicological mechanisms is warranted.